Alpha 2.0
Login Register
» Authors » Michela Efficace

Michela Efficace

Explore the profile of Michela Efficace including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 229
Followers 0
Related Specialties
Cardiology & Vascular Diseases
Pulmonary Medicine
General Surgery
Top 10 Co-Authors
Nazzareno Galie
Maurice Beghetti
Andjela Kusic-Pajic
Alain Fraisse
Xavier Jais
Damien Bonnet
Yves Dulac
Kelly Papadakis
Marion Delcroix
D Dunbar Ivy
Published In
Eur Respir J
Int J Cardiol
J Thorac Cardiovasc Surg
RMD Open
Circulation
Affiliations
Soon will be listed here.
Recent Articles
1.
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
McInnes I, Sewerin P, Sharaf M, Efficace M, Lavie F, Zimmermann M, et al.
RMD Open . 2024 Dec; 10(4. PMID: 39672591
Objectives: To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor...
2.
Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO Phase 3 trial and open-label extension
Clift P, Berger F, Sondergaard L, Antonova P, Disney P, Nicolarsen J, et al.
J Thorac Cardiovasc Surg . 2024 Aug; 169(2):385-394.e5. PMID: 39216715
Objectives: The efficacy and safety of macitentan, an endothelin receptor antagonist, were assessed in a 52-week, prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessing the efficacy and safety of macitentan...
3.
Evaluation of Macitentan in Patients With Eisenmenger Syndrome
Gatzoulis M, Landzberg M, Beghetti M, Berger R, Efficace M, Gesang S, et al.
Circulation . 2018 Dec; 139(1):51-63. PMID: 30586694
Background: Eisenmenger syndrome describes congenital heart disease-associated severe pulmonary hypertension accompanied by right-to-left shunting. The multicenter, double-blind, randomized, placebo-controlled, 16-week, phase III MAESTRO study (Macitentan in Eisenmenger Syndrome to Restore...
4.
Macitentan in pulmonary hypertension due to left ventricular dysfunction
Vachiery J, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, et al.
Eur Respir J . 2018 Feb; 51(2). PMID: 29437943
The MELODY-1 study evaluated macitentan for pulmonary hypertension because of left heart disease (PH-LHD) in patients with combined post- and pre-capillary PH.63 patients with PH-LHD and diastolic pressure gradient ≥7 ...
5.
Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58]
Berger R, Haworth S, Bonnet D, Dulac Y, Fraisse A, Galie N, et al.
Int J Cardiol . 2016 Sep; 223:1072-1073. PMID: 27623401
No abstract available.
6.
FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion
Berger R, Haworth S, Bonnet D, Dulac Y, Fraisse A, Galie N, et al.
Int J Cardiol . 2015 Sep; 202:52-8. PMID: 26386921
Background: A novel formulation of bosentan was evaluated in children with pulmonary arterial hypertension (PAH) in FUTURE-1, which characterized its pharmacokinetic and clinical profile. The subsequent phase III, open-label, long-term...
7.
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
Simonneau G, Torbicki A, Hoeper M, Delcroix M, Karlocai K, Galie N, et al.
Eur Respir J . 2012 Feb; 40(4):874-80. PMID: 22362844
In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension...